Skip to main content

Table 1 In vitro susceptibilities of Gram-negative strains obtained from the ATLAS program, 2012–2016

From: Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime–avibactam: a surveillance study from the ATLAS program (2012–2016)

Organism/antibiotic

No. of isolates

MIC50

MIC90

MIC range

CLSIa

EUCAST

S%

I%

R%

S%

I%

R%

Escherichia coli

Ceftaroline

21903

0.12

256

0.015–256

66.5

2.6

30.9

66.5

0

33.5

Ceftazidime–avibactam

21903

0.12

0.25

0.015–256

99.8

0

0.2

99.8

0

0.2

Ceftazidime

21903

0.25

32

0.015–256

79.2

3.0

17.8

74.0

5.1

20.8

Cefepime

21903

0.12

32

0.12–32

76.2

4.7

19.1

74.6

3.6

21.8

Pip-taz

21903

2

16

0.25–256

90.3

4.6

5.1

84.8

5.4

9.8

Doripenem

21903

0.03

0.06

0.008–16

99.6

0.1

0.3

99.6

0.1

0.3

Imipenem

21903

0.25

0.25

0.03–16

99.1

0.4

0.5

99.5

0.4

0.2

Meropenem

21903

0.03

0.06

0.004–16

99.5

0.1

0.4

99.6

0.2

0.2

Levofloxacin

21903

0.25

16

0.004–16

62.3

1.7

36.0

58.8

2.8

38.4

Tigecycline

21903

0.25

0.5

0.015–16

99.8

0.2

0

99.0

0.8

0.2

Amikacin

21903

2

8

0.25–64

98.2

0.9

0.9

94.5

3.7

1.8

Colistin

13964

0.5

1

0.06–16

NA

NA

NA

99.5

0

0.5

Aztreonam

21903

0.12

64

0.015–256

76.0

3.1

20.9

72.3

3.7

24.0

Klebsiella pneumoniae

Ceftaroline

18114

0.25

256

0.015–256

57.5

2.0

40.5

57.5

0

42.5

Ceftazidime–avibactam

18114

0.12

1

0.015–256

98.8

0

1.2

98.8

0

1.2

Ceftazidime

18114

0.25

128

0.015–256

64.3

1.9

33.8

61.6

2.7

35.7

Cefepime

18114

0.12

32

0.12–32

65.1

6.0

28.9

63.7

3.2

33.1

Pip/taz

18114

4

256

0.25–256

73.0

7.8

19.2

64.4

8.6

27.0

Doripenem

18114

0.06

0.5

0.008–16

91.6

1.0

7.4

91.6

1.0

7.4

Imipenem

18114

0.25

1

0.03–16

90.3

1.9

7.8

92.2

2.4

5.5

Meropenem

18114

0.06

0.5

0.004–16

91.1

1.1

7.9

92.1

2.0

5.9

Levofloxacin

18114

0.12

8

0.004–16

73.2

3.1

23.7

61.8

9.1

29.1

Tigecycline

18114

0.5

2

0.015–16

96.4

3.1

0.5

88.2

8.2

3.6

Amikacin

18114

1

8

0.25–64

93.6

3.0

3.4

91.0

2.6

6.4

Colistin

12884

0.5

1

0.06–16

NA

NA

NA

96.3

0

3.7

Aztreonam

18114

0.12

256

0.015–256

64.2

1.0

34.8

62.4

1.8

35.8

Enterobacter cloacae

Ceftaroline

4330

0.5

256

0.015–256

60.0

3.1

37.0

60.0

0.0

40.1

Ceftazidime–avibactam

4330

0.25

1

0.015–256

97.8

0.0

2.2

97.8

0.0

2.2

Ceftazidime

4330

0.5

128

0.015–256

67.3

1.4

31.3

64.0

3.3

32.7

Cefepime

4330

0.12

32

0.12–32

78.5

8.8

12.7

73.3

10.8

15.9

Pip-taz

4330

4

256

0.25–256

75.3

8.0

16.7

69.9

5.4

24.7

Doripenem

4330

0.06

0.25

0.008–16

96.8

0.4

2.9

96.8

0.4

2.9

Imipenem

4330

0.5

1

0.03–16

93.1

3.5

3.4

96.6

2.0

1.5

Meropenem

4330

0.06

0.12

0.004–16

96.8

0.6

2.6

97.4

1.3

1.3

Levofloxacin

4330

0.06

4

0.004–16

88.8

2.8

8.4

80.8

5.7

13.5

Tigecycline

4330

0.5

1

0.015–16

96.3

3.2

0.5

90.1

6.2

3.7

Amikacin

4330

2

4

0.25–64

97.6

0.9

1.6

96.0

1.6

2.4

Colistin

2889

0.5

1

0.12–16

NA

NA

NA

93.7

0.0

6.3

Aztreonam

4330

0.12

64

0.015–256

68.2

1.4

30.4

65.8

2.4

31.8

Citrobacter freundii

Ceftaroline

2327

0.25

128

0.015–256

61.9

2.1

36.0

61.9

0

38.1

Ceftazidime–avibactam

2327

0.12

0.5

0.015–256

98.5

0

1.5

98.5

0

1.5

Ceftazidime

2327

0.5

128

0.015–256

68.0

1.9

30.1

64.3

3.8

32.0

Cefepime

2327

0.12

4

0.12–32

89.8

3.6

6.7

84.4

7.3

8.4

Pip-taz

2327

4

128

0.25–256

77.1

12.0

11.0

70.5

6.6

23.0

Doripenem

2327

0.06

0.12

0.008–16

97.9

0.3

1.8

97.9

0.3

1.8

Imipenem

2327

0.5

2

0.03–16

88.9

8.5

2.6

97.4

2.1

0.5

Meropenem

2327

0.03

0.06

0.004–16

97.7

0.5

1.8

98.2

1.2

0.6

Levofloxacin

2327

0.12

4

0.008–16

87.0

4.0

9.0

76.5

6.2

17.3

Tigecycline

2327

0.5

1

0.015–8

98.9

1.1

0

94.9

4.0

1.1

Amikacin

2327

2

4

0.25–64

98.4

0.4

1.2

97.1

1.3

1.6

Colistin

1593

0.5

1

0.06–16

NA

NA

NA

99.6

0

0.4

Aztreonam

2327

0.25

64

0.015–256

69.2

2.4

28.4

66.2

3.1

30.8

Proteus mirabilis

Ceftaroline

3950

0.12

128

0.015–256

79.4

2.0

18.6

79.4

0

20.6

Ceftazidime–avibactam

3950

0.03

0.06

0.015–256

99.7

0

0.3

99.7

0

0.3

Ceftazidime

3950

0.06

1

0.015–256

95.2

1.7

3.1

91.1

4.1

4.8

Cefepime

3950

0.12

8

0.12–32

88.2

3.4

8.5

86.9

2.9

10.3

Pip-taz

3950

0.5

1

0.25–256

98.5

0.9

0.6

97.7

0.8

1.5

Doripenem

3950

0.25

0.5

0.008–16

98.4

1.0

0.6

98.4

1.0

0.6

Imipenem

3950

2

4

0.03–16

25.8

45.9

28.3

71.7

27.7

0.6

Meropenem

3950

0.06

0.12

0.004–16

99.6

0.2

0.3

99.8

0.2

0.1

Levofloxacin

3950

0.12

8

0.015–16

76.6

5.5

17.9

64.9

4.5

30.6

Tigecycline

3950

2

8

0.03–16

52.2

37.3

10.5

20.9

31.3

47.8

Amikacin

3950

4

8

0.25–64

95.6

1.1

3.4

91.5

4.1

4.4

Colistin

2412

16

16

0.25–16

NA

NA

NA

0.5

0

99.5

Aztreonam

3950

0.015

0.5

0.015–256

95.9

0.8

3.3

93.1

2.9

4.1

Pseudomonas aeruginosa

Ceftaroline

16014

16

256

0.015–256

NA

NA

NA

NA

NA

NA

Ceftazidime–avibactam

16014

2

8

0.015–256

91.9

0

8.1

91.9

0

8.1

Ceftazidime

16014

4

64

0.06–256

76.7

4.6

18.8

76.7

0

23.4

Cefepime

16014

4

32

0.12–32

78.4

11.2

10.5

78.4

0

21.6

Pip-taz

16014

8

256

0.25–256

68.9

13.8

17.3

68.9

0

31.2

Doripenem

16013

0.5

8

0.008–16

74.3

7.6

18.2

67

7.2

25.8

Imipenem

16014

2

16

0.03–16

63.4

8.2

28.4

71.6

4.5

23.9

Meropenem

16014

0.5

16

0.008–16

72.5

6.0

21.5

72.5

11.9

15.6

Levofloxacin

16014

1

8

0.004–16

70.4

6.8

22.9

61.7

0

38.3

Amikacin

16014

4

16

0.25–64

90.4

2.7

6.9

85.9

4.5

9.6

Colistin

12449

1

2

0.06–16

96.6

0

3.4

96.6

0

3.4

Aztreonam

16014

8

32

0.015–256

NA

NA

NA

3.9

73.4

22.8

Acinetobacter baumannii

Ceftaroline

3567

256

256

0.015–256

NA

NA

NA

NA

NA

NA

Ceftazidime–avibactam

3567

32

128

0.03–256

NA

NA

NA

NA

NA

NA

Ceftazidime

3567

64

256

0.015–256

30.1

2.4

67.5

NA

NA

NA

Cefepime

3567

32

32

0.12–32

29.9

10.4

59.7

NA

NA

NA

Pip-taz

3567

256

256

0.25–256

25.4

3.7

70.9

NA

NA

NA

Doripenem

3567

8

16

0.015–16

33.2

1.4

65.4

30.4

2.8

66.8

Imipenem

3567

16

16

0.03–16

33.8

1.2

65.0

33.8

2.7

63.5

Meropenem

3567

16

16

0.015–16

32.8

1.6

65.6

32.8

3.5

63.7

Levofloxacin

3567

8

16

0.03–16

29

9.6

61.4

26.1

1.0

73

Tigecycline

3567

1

2

0.015–16

NA

NA

NA

NA

NA

NA

Amikacin

3567

64

64

0.25–64

42.5

5.8

51.7

40.2

2.3

57.5

Colistin

2404

1

2

0.06–16

94.3

0

5.7

94.3

0

5.7

Aztreonam

3567

64

256

0.015–256

NA

NA

NA

NA

NA

NA

  1. CLSI Clinical Laboratory and Standards Institute, EUCAST European Committee on Antimicrobial Susceptibility Testing, NA not applicable
  2. aCefepime CLSI susceptibility for Enterobacteriaceae adopted the susceptible, susceptible-dose-dependent, and resistant categories